Medicare curtails 'breakthrough' device payment pathways, exposing systemic gaps in approval, reimbursement, and health equity
Original framing: “STAT+: Medicare eliminates key pathways used by ‘breakthrough’ devices for extra payments” — STAT News
Robust scientific evidence demands longitudinal real‑world data, yet the breakthrough pathway often relies on limited surrogate endpoints, undermining the predictive validity of early efficacy claims.
The curtailment of breakthrough device payment pathways forces a reckoning with a legacy of accelerated approvals that have repeatedly compromised patient safety.
By integrating outcome‑based reimbursement, inclusive governance, and international surveillance standards, the system can transform profit‑driven incentives into evidence‑driven stewardship. Indigenous and marginalized perspectives highlight the cultural and equity dimensions missing from current debates, while scientific and future‑modelling analyses underscore the fiscal and health risks of inaction. Together, these strands suggest a re‑imagined regulatory ecosystem where innovation proceeds hand‑in‑hand with accountability, cultural humility, and global collaboration.